FRENCH vaccine specialist company Sanofi Pasteur announced last week that it reached a deal to buy Protein Sciences, thereby accessing it's quadrivalent influenza vaccine Flublok, according to Nasdaq GlobeNewswire.
A Sanofi spokesperson highlighted Flublok is the only FDA approved recombinant protein-based influenza vaccine.
Sanofi Pasteur executive vp David Loew said the acquisition "will allow us to broaden our [influenza] portfolio with the addition of a non-egg based vaccine."
The agreement sees Sanofi pay $650m upfront to Protein Sciences and up to $100m upon the achievement of certain milestones.
The transaction is expected to close in the third quarter.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Jul 17